Percutaneous Atriotomy for Levoatrial–to–Coronary Sinus Shunting in Symptomatic Heart Failure: First-in-Human Experience
Heart Failure With Improved Ejection Fraction-Is it Possible to Escape One’s Past?
Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failure
Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors
Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry
Association of Cardiovascular Disease With Respiratory Disease
The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHERE
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)